Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 11/20 | 1.00 |
| ▸ | MAX | P61244 | 7/20 | 0.81 |
| ▸ | MEN1 | O00255 | 9/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.70 |
| ▸ | IDO1 | P14902 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386206 | 1.00 | MYC (1.00) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL16107698 | 0.95 | MYC (0.91) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL16139724 | 0.90 | MYC (0.82) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL17927377 | 0.87 | MYC (0.77) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL17927315 | 0.85 | MYC (0.73) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL17934467 | 0.85 | MYC (0.73) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL16139687 | 0.85 | MYC (0.80) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL16139693 | 0.85 | MYC (0.79) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL16139677 | 0.83 | MYC (0.81) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL16107551 | 0.83 | MYC (0.85) | MYCMAXMEN1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026343-B2 | Pharmacologic inhibition of Myc function | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-04-11 | — | — | US | claimed |
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | claimed |
| WO-2003105759-A2 | PHARMACOLOGIC INHIBITION OF MYC FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-12-24 | — | — | WO | claimed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| US-11852631-B2 | Biomarkers predictive of anti-immune checkpoint response | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230277574-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| US-20140296307-A1 | POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014039908-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2014-03-13 | — | — | WO | disclosed |
| US-8637556-B2 | Linked Myc-max small molecule inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2012055170-A1 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES | THE UNIVERSITY OF HONG KONG (CN) | 2012-05-03 | — | — | WO | disclosed |
| US-20120107317-A1 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES | THE UNIVERSITY OF HONG KONG (CN) | 2012-05-03 | — | — | US | disclosed |
| WO-2010083404-A2 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-07-22 | — | — | WO | disclosed |
| US-7026343-B2 | Pharmacologic inhibition of Myc function | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | disclosed |
| WO-2003105759-A2 | PHARMACOLOGIC INHIBITION OF MYC FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296307-A1 | POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY | MYC, MYCBP, MKI67 | MYC 1/4885MAX 4/4885MEN1 204/4885 |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | MYC 12/4885MAX 2554/4885MEN1 66/4885 |
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | MYCBP, MYC, MYCBP2 | MYC 2/4885MAX 5/4885MEN1 1041/4885 |
| US-20230277574-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | MYC 12/4885MAX 2554/4885MEN1 66/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | MYC 8/4885MAX 3943/4885MEN1 254/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | MYC 6/4885MAX 1556/4885MEN1 82/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | MYC 6/4885MAX 1556/4885MEN1 82/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | MYC 12/4885MAX 2554/4885MEN1 66/4885 |
| US-11963968-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | MYC 12/4885MAX 2554/4885MEN1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.